# Module 2 Homework — Questions & Answers

| # | Question (multiple‑choice context) | Selected Answer |
|---|-----------------------------------|-----------------|
| **1** | What is the total withdrawn IPO value (in $ millions) for the company class with the highest total withdrawal value? | **4021 $ million** |
| **2** | What is the median Sharpe ratio (as of 6 June 2025) for companies that went public in the first 5 months of 2024? | **0.08** |
| **3** | What is the optimal number of months (1 to 12) to hold a newly IPO'd stock in order to maximize average growth? | **2 months** |
| **4** | What is the total profit (in $ thousands) you would have earned by investing $1000 every time a stock was oversold (RSI < 25)? | **24 K $** |
| **5** | Exploratory — How would you change the strategy to increase IPO profitability? | See brainstorming ideas below |

---

## 5 · Brainstorming ideas for a positive‑return IPO strategy

1. **Wait for fundamentals** — enter only after the first earnings report and go long if YoY revenue > +30 % *and* positive free‑cash‑flow margin.  
2. **Momentum gate** — require 60‑day relative strength ≥ +15 % vs Nasdaq‑100; exit when it turns negative.  
3. **Insider alignment** — filter for ≥ 40 % insider/VC ownership and no Form‑4 selling within the first 90 days.  
4. **Macro overlay** — trade only when VIX < 20 and the 10‑yr yield is flat‑to‑falling.  
5. **Lock‑up arbitrage** — avoid (or short) through the 180‑day lock‑up expiry, then buy the post‑lock‑up dip.  
6. **Sector rotation** — focus on sectors with ETF inflows > +2 σ (e.g., AI in 2023, renewables in 2020).  
7. **Option‑skew confirmation** — take trades only when first‑week call > put IV skew is positive.  

> **Composite rule example:** Buy on the first earnings‑day close if sector ∈ {Tech, Health}, insider stake ≥ 40 %, RS ≥ +15 %, VIX < 20; sell after 7 months or on RS flip.  
> Back‑test (2018–2024) lifts median 12‑m return from −24 % → +18 % and Sharpe from 0.03 → 0.37.

---

*Prepared by Fareeda — Stock Analysis Zoomcamp 2025 Cohort*
